Searchable abstracts of presentations at key conferences on calcified tissues

ba0001oc4.4 | Osteoblasts and osteocytes | ECTS2013

Glucocorticoid exposure reduces expression of sclerostin in bone marrow stromal cells

Thiele Sylvia , Rauch Alexander , Tuckermann Jan P , Hofbauer Lorenz C , Rauner Martina

Glucocorticoids (GC) are effective drugs in the treatment of inflammatory diseases, including various forms of arthritis. However, their use is limited by negative effects on bone mass and strength, resulting in increased osteoporotic fractures. Conditional knockout mice demonstrated that the GR in osteoblasts is essential for GC-dependent bone loss. Recent studies show that GC profoundly inhibit Wnt signaling by stimulating the expression of Wnt antagonists such as dickkopf-1...

ba0001pp18 | Arthritis and other joint diseases: translational and clinical | ECTS2013

Milk fat globule-epidermal growth factor 8 is a critical determinant of bone mass and alters the course of inflammation in arthritis

Sinningen Kathrin , Thiele Sylvia , Grossklaus Sylvia , Udey Mark , Hofbauer Lorenz C , Chavakis Triantafyllos , Rauner Martina

Milk fat globule-epidermal growth factor 8 (MFG-E8) is a glycoprotein that controls the engulfment of apoptotic cells and exerts anti-inflammatory effects. It has been implicated in the pathogenesis of several diseases, but its role in the bone microenvironment is still unknown. Here we tested the hypothesis that MFG-E8 also regulates bone metabolism and the development of arthritis.MFG-E8 expression was detected in mouse bones and primary murine osteobl...

ba0001pp145 | Cancer and bone: basic, translational and clinical | ECTS2013

Synergistic anti-tumour effects on human breast cancer cells by mevalonate pathway inhibitors atorvastatin and zoledronic acid

Gobel Andy , Thiele Stefanie , Rauner Martina , Lorenz C Hofbauer , Tilman D Rachner

Introduction: Bone metastases represent a frequent complication of breast cancer and are characterized by increased tumour-driven activation of osteoclasts and subsequent bone loss. Aminobisphosphonates inhibit osteoclast function and are established therapies of skeletal metastases. Similar to statins, they block the mevalonate pathway and are thought to have direct anti-tumour effects. Here, we report on the anti-tumour potential of a sequential inhibition of the mevalonate ...

ba0001pp228 | Cell biology: osteoclasts and bone resorption | ECTS2013

Bisphosphonates differently affect jaw and long-bone marrow cells

Vermeer Jenny A F , Jansen Ineke D C , Renders Greetje A P , de Vries Teun J , Everts Vincent

Bisphosphonates (BPs) such as zoledronic acid (ZA) are widely used to treat bone diseases. The use of BPs can lead to osteonecrosis of the jaw (ONJ), but it is not clear why in particular the jaw bone is affected. Previously, it was shown that osteoclasts derived from different bone sites have different properties. We hypothesize that BPs have distinct effects on bone-site specific osteoclasts or precursors. To investigate this, female C57BL/6J mice were injected intraperitone...

ba0001pp280 | Genetics | ECTS2013

Association between dentinogenesis imperfecta and mutations in COLIA1 and COLIA2 genes

Andersson Kristofer , Dahllof Goran , Astrom Eva , Rubin C-J , Kindmark A , Lindahl Katarina , Ljunggren Osten , Malmgren Barbro

Introduction: Dentinogenesis imperfecta (DI) is a common dental aberration in patients with osteogenesis imperfecta (OI). Mutations that cause abnormal collagen chains will cause more serious types of OI and it has been claimed that DI should be a marker for qualitative defected collagen. It has also been supposed that normal development of teeth may be more dependent on normal α2(I) than normal α1(I) chains which are encoded by COLIA2 and COLIA1 ge...

ba0001pp433 | Osteoporosis: treatment | ECTS2013

Denosumab is associated with progressive improvements in hip cortical mass and thickness

Poole K , Treece G , Gee A , Brown J P , McClung M R , Wang A , Libanati C

Denosumab (DMAb) significantly improves bone strength at the hip, estimated by FEA from QCT scans, from baseline (B/L) and vs placebo (Pbo) (Keaveny ASBMR 2010). We determined the extent and distribution of mass and thickness changes at the proximal femur, a key skeletal site for fracture risk, using a novel cortical bone mapping technique on the same serial QCT scans. A FREEDOM substudy included 80 women who underwent hip QCT scanning at B/L and months 12, 24 and 36 during DM...

ba0001pp500 | Other diseases of bone and mineral metabolism | ECTS2013

IFITM5 c.−14C>T mutation causes variable type V osteogenesis imperfecta phenotype and decreased COL1A1 expression but increased mineralization by cultured proband osteoblasts

Reich Adi , Bae Alison S , Barnes Aileen M , Cabral Wayne A , Chitayat David , Marini Joan C

Introduction: Osteogenesis imperfecta (OI) is a genetically heterogeneous disorder characterized by bone fragility. OI type V, with autosomal dominant inheritance, is characterized by ossification of the forearm interosseus membrane, radiodense metaphyseal bands, propensity for hyperplastic callus formation, and mesh-like lamellation on bone histology. Type V OI probands are reported to have white sclerae and normal teeth. Recent reports identified the cause of type V OI as a ...

ba0002p108 | (1) | ICCBH2013

Antenatal glucocorticoid injections do not aggravate stress-induced bone loss in young adult mice

Henneicke Holger , Gasparini Sylvia J , Brennan-Speranza Tara C , Zhou Hong , Seibel Markus J

Antenatal glucocorticoid (GC) injections are not only used to enhance fetal lung maturation in preterm children but also for the treatment of maternal conditions such as autoimmune diseases or infections. Animal models and clinical studies suggest that the regulation of the hypothalamic–pituitary–adrenal axis is altered in the offspring of GC-treated mothers with increased sensitivity to stress.Objective: The aim of this study is i) to define t...